
    
      To evaluate the clinical efficacy of a treatment with empagliflozin in refractory diabetes
      mellitus patients with insulin resistance (insulin resistance syndrome, lipoatrophic diabetes
      mellitus) by using the HbA1c change at Week 24 of treatment from baseline
    
  